Corbus Regulatory Monday, November 16, 2026 +0.60 Positive

Corbus presents Phase 1b CRB-913 weight loss data

Corbus Pharmaceuticals presented data from the CANYON-1 Phase 1b trial showing statistically significant weight loss and a favorable safety profile for its oral, non-incretin obesity treatment CRB-913.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed